Background And Objective: High LIMCH1 expression in lung and renal cancer is determined as a favorable prognostic factor. However, prognostic value of LIMCH1 expression in breast cancer has not been studied yet. Therefore, this study was performed to determine the prognostic value of LIMCH1 expression in breast cancer patients.
Methods: This retrospective study included 89 patients with invasive breast carcinoma of no special type. These patients referred to Cancer Research Institute of Tomsk National Research Medical Center from 2007 to 2018. LIMCH1 protein expression in tumor cells was detected by immunohistochemical analysis in this study. Statistical analysis was done to investigate the possible relationship between LIMCH1 protein expression and clinicopathological parameters, risk of metastasis, distant metastasis free survival, and overall survival.
Results: IHC analysis of breast cancer tissue samples revealed that LIMHC1 protein expression was found in 29.2% (26/89) of the cases. Lymph node and distant metastases were more frequent in patients with LIMCH1 protein expression. LIMCH1 protein expression increased the risk of distant metastasis based on our findings. LIMCH1 protein affected metastatic-free survival regardless of the T, as well as other clinical and pathological parameters (p=0.0146, HR=3.2058 (1.26; 8.17)). Moreover, LIMCH1 protein expression was associated with worse overall survival (p=0.0071, HR=2.73 (1.28; 5.85)) in our breast cancer patients.
Conclusion: LIMCH1 protein expression was associate with metastases development, providing prognostic stratification. In breast cancer, LIMCH1 protein expression was found as an unfavorable prognostic factor of distant metastasis-free survival based on our findings.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930957 | PMC |
| http://dx.doi.org/10.31557/APJCP.2022.23.11.3947 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integrative bioinformatics and immunohistochemical analysis unravel the prognostic significance and immunological implication of LIMCH1 in breast cancer: a retrospective study.
Sci Rep
January 2025
Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, 238 Ziyang Road, Wuhan, 430060, Hubei, People's Republic of China.
The current mortality rates for breast cancer underscore the need for better prognostic tools; moreover, LIM and calponin homology domain 1 (LIMCH1), which is a protein with dual roles in cancer, is a promising candidate for investigation. This study employed an integrative approach combining bioinformatics analysis of The Cancer Genome Atlas (TCGA) cohort and clinical immunohistochemistry (IHC) cohort data. We analysed LIMCH1 expression patterns, its associations with clinicopathological features and prognosis, and its impact on the tumour immune microenvironment (TIME).
View Article and Find Full Text PDFMapping RANKL- and OPG-expressing cells in bone tissue: the bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect.
Bone Res
October 2024
Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Denosumab is a monoclonal anti-RANKL antibody that inhibits bone resorption, increases bone mass, and reduces fracture risk. Denosumab discontinuation causes an extensive wave of rebound resorption, but the cellular mechanisms remain poorly characterized. We utilized in situ hybridization (ISH) as a direct approach to identify the cells that activate osteoclastogenesis through the RANKL/OPG pathway.
View Article and Find Full Text PDFProtein and mRNA Expression in Uveal Melanoma Cell Lines Are Related to GNA and BAP1 Mutation Status.
Invest Ophthalmol Vis Sci
July 2024
Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
Article Synopsis
- The study aimed to better classify uveal melanoma (UM) cell lines by examining their genetic and expression profiles, particularly focusing on identifying any underlying genetic causes for their behavior.
- Researchers analyzed 14 UM cell lines using techniques like next-generation sequencing and SNP arrays to assess protein and mRNA expression, and to identify genetic variants.
- Results indicated that cell lines Mel285 and Mel290, which do not have typical UM mutations, possess distinct genetic alterations and expression profiles, making them potentially unsuitable for research on therapeutic targets for UM.
Actin-dependent recruitment of AGO2 to the zonula adherens.
Mol Biol Cell
December 2023
Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, 173 Ashley Avenue, Charleston, SC 29425.
Adherens junctions are cadherin-based structures critical for cellular architecture. E-cadherin junctions in mature epithelial cell monolayers tether to an apical actomyosin ring to form the zonula adherens (ZA). We have previously shown that the adherens junction protein PLEKHA7 associates with and regulates the function of the core RNA interference (RNAi) component AGO2 specifically at the ZA.
View Article and Find Full Text PDFThe role of alternative splicing in skeletal muscle function.
Life Sci Alliance
June 2023
Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, USA
Article Synopsis
- Postnatal skeletal muscle development involves significant changes in gene splicing, essential for adapting muscle function from fetal to adult stages.
- The protein LIMCH1 is crucial in this process, with two spliced isoforms: uLIMCH1 (fetal) and mLIMCH1 (muscle-specific), which are produced differently during and after birth.
- Knockout studies using CRISPR/Cas9 on mLIMCH1 in mice showed that the lack of this isoform leads to muscle weakness and impaired calcium handling, highlighting its importance in muscle function and the broader implications for conditions like muscular dystrophy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!